Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

BACKGROUND: Thirty to 40 % of non-small cell lung cancer (NSCLC) patients developed higher hypertriglyceridemia in the process of treatment with bexarotene. And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients. So, we will exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Xinghao, Mao, Feng, Shen, Shengping, Shentu, Yang, Wang, Jiejun, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896077/
https://www.ncbi.nlm.nih.gov/pubmed/29642873
http://dx.doi.org/10.1186/s12885-018-4224-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896077/
https://www.ncbi.nlm.nih.gov/pubmed/29642873
http://dx.doi.org/10.1186/s12885-018-4224-x

Ejemplares similares